Connection

Daniel Duerschmied to Angiotensin Receptor Antagonists

Back to Details
This is a "connection" page, showing publications Daniel Duerschmied has written about Angiotensin Receptor Antagonists.
Daniel Duerschmied
Connection Strength
0.087
Angiotensin Receptor Antagonists
  1. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respir Med. 2021 08; 9(8):863-872.
    View in: PubMed
    Score: 0.070
  2. Response to "How Important Is the Assessment of Soluble ACE-2 in COVID-19?" Am J Hypertens. 2021 04 02; 34(3):298.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.